Research and Markets (http://www.researchandmarkets.com/research/xskc83/acromegaly) has announced the addition of the "Acromegaly - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Acromegaly, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
It also reviews key players involved in the therapeutic development for Acromegaly and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Introduction
- Acromegaly Overview
- Therapeutics Development
- Pipeline Products for Acromegaly - Overview
- Pipeline Products for Acromegaly - Comparative Analysis
- Acromegaly - Therapeutics under Development by Companies
- Acromegaly - Therapeutics under Investigation by Universities/Institutes
- Acromegaly - Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Acromegaly - Products under Development by Companies
- Acromegaly - Products under Investigation by Universities/Institutes
-
Acromegaly - Companies Involved in Therapeutics Development
Companies Mentioned:
- Aegis Therapeutics, LLC
- Antisense Therapeutics Limited
- Chiasma, Inc.
- Crinetics Pharmaceuticals, Inc.
- DexTech Medical AB
- Foresee Pharmaceuticals, LLC
- Ipsen S.A.
- Isis Pharmaceuticals, Inc.
- Italfarmaco S.p.A.
- Novartis AG
- Peptron, Inc.
- Sompharmaceuticals S.A.
-
Strongbridge Biopharma plc
For more information visit http://www.researchandmarkets.com/research/xskc83/acromegaly
View source version on businesswire.com: http://www.businesswire.com/news/home/20160129005731/en/